QUVIVIQ
Pronunciation: dar-i-doe-REX-ant (kyoo-VI-vik)


What it isDual orexin receptor antagonist; insomnia.
Why this oneShortest half-life of the orexin antagonists, so next-morning impairment is least.
What limits itSomnolence remains, and seven hours must remain before waking. CYP3A4-dependent; Schedule IV.
Animated chart of estimated U.S. prescriptions per year, Sleep meds (1869–2026). Daridorexant enters in 2022 (estimated).
Principal riskSomnolence; allow seven hours before waking
Legacy pregnancy categoryNot assigned — PLLR-era drug
Defining liabilityNext-day somnolence, abnormal sleep behaviors and additive CNS depression.
Read the full label on DailyMed ↗
NO BOXED WARNINGS
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Insomnia (sleep onset and/or maintenance) | Adults | 25-50 mg QHS | 25-50 mg QHS | 50 mg QHS |
Renal Undefined
Hepatic Moderate (Child-Pugh 7-9): max 25 mg QHS. Severe (>=10): not recommended.
No more than once per night.
Available strengths
Pregnancy No human data; pregnancy exposure registry available.
Lactation Present in human milk in low amounts (<1% RID); monitor breastfed infant for excessive sedation.
| Strength | #/mo | generic $/mo | brand $/mo | CostPlus | |
|---|---|---|---|---|---|
| 25 mg | tab | 30 qd | — | $501.14 | not offered |
| 50 mg | tab | 30 qd | — | $501.14 | not offered |
Generic entry2034 est.
Open Daridorexant in the interactive console ↗

Open Daridorexant in the interactive console ↗